(Q40262479)

19 September 2017

Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab (English)

1 reference

19 September 2017

0 references

1 reference

1 reference

13

A Eggermont

0 references

Nathalie Chaput

1

N Chaput

0 references

Caroline Robert

17

C Robert

0 references

Emilie Lanoy

15

E Lanoy

0 references

Patricia Lepage

P Lepage

2

0 references

author name string

N Chaput

1

1 reference

19 September 2017

C Coutzac

3

1 reference

19 September 2017

E Soularue

4

1 reference

19 September 2017

K Le Roux

5

1 reference

19 September 2017

C Monot

6

1 reference

19 September 2017

L Boselli

7

1 reference

19 September 2017

E Routier

8

1 reference

19 September 2017

L Cassard

9

1 reference

19 September 2017

M Collins

10

1 reference

19 September 2017

T Vaysse

11

1 reference

19 September 2017

L Marthey

12

1 reference

19 September 2017

V Asvatourian

14

1 reference

19 September 2017

C Mateus

16

1 reference

19 September 2017

F Carbonnel

18

1 reference

19 September 2017

27 March 2017

1 reference

19 September 2017

1 reference

19 September 2017

28

1 reference

19 September 2017

6

1 reference

19 September 2017

1368-1379

1 reference

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

19 September 2017

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX108

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX108

Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX108

The blockade of immune checkpoints in cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX108

Immune Checkpoint Blockade in Cancer Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX108

Management of immune-related adverse events and kinetics of response with ipilimumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX108

Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX108

Systematic review: colitis associated with anti-CTLA-4 therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX108

Cancer Immunotherapy with Anti-CTLA-4 Monoclonal Antibodies Induces an Inflammatory Bowel Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX108

Inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX108

Twin study indicates loss of interaction between microbiota and mucosa of patients with ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX108

Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX108

Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX108

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX108

Genetic basis for clinical response to CTLA-4 blockade in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX108

Alterations of the dominant faecal bacterial groups in patients with Crohn's disease of the colon

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX108

Anti-CTLA-4 therapy results in higher CD4+ICOShi T cell frequency and IFN-gamma levels in both nonmalignant and malignant prostate tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX108

The inflammatory status of old age can be nurtured from the intestinal environment

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX108

Richness of human gut microbiome correlates with metabolic markers

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX108

Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX108

Metabolism of linoleic acid by human gut bacteria: different routes for biosynthesis of conjugated linoleic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX108

Gut microbiome-derived metabolites modulate intestinal epithelial cell damage and mitigate graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX108

The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX108

Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX108

Reciprocal interactions of the intestinal microbiota and immune system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX108

Thymus-derived regulatory T cells contribute to tolerance to commensal microbiota

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX108

Altered intestinal microbiota and blood T cell phenotype are shared by patients with Crohn's disease and their unaffected siblings.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX108

Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX108

The ICOS/ICOSL pathway is required for optimal antitumor responses mediated by anti-CTLA-4 therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX108

CTLA-4 blockade increases IFNgamma-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX108

IL-2 therapy promotes suppressive ICOS+ Treg expansion in melanoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX108

The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX108

Phase I clinical trial combining imatinib mesylate and IL-2: HLA-DR(+) NK cell levels correlate with disease outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX108

Selective IL-2 responsiveness of regulatory T cells through multiple intrinsic mechanisms supports the use of low-dose IL-2 therapy in type 1 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX108

Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDX108

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDX108

1 reference

19 September 2017

1 reference